The boom in prescriptions for an overdose-reversing drug and the decline of high-dosage opioid prescriptions contributed to the drop in deaths. But 68,000 people still died by drug overdoses in 2018.
Prescriptions of the overdose-reversing drug naloxone are soaring, and experts say that could be a reason overdose deaths have stopped rising for the first time in nearly three decades.
The number of naloxone prescriptions dispensed by U.S. retail pharmacies doubled from 2017 to last year, rising from 271,000 to 557,000, health officials reported Tuesday.
The United States is in the midst of the deadliest drug overdose epidemic in its history. About 68,000 people died of overdoses last year, according to preliminary government statistics reported last month, a drop from the more than 70,000 in 2017.
“One could only hope that this extraordinary increase in prescribing of naloxone is contributing to that stabilization or even decline of the crisis,” said Katherine Keyes, a Columbia University drug abuse expert.
About two-thirds of U.S. overdose deaths involve some kind of opioid, a class of drugs that includes heroin, certain prescription painkillers and illicit fentanyl. Naloxone is a medication that can reverse opioid overdoses, restoring breathing and bringing someone back to consciousness. It first went on sale in 1971 as an injection. An easier-to-use nasal spray version, Narcan, was approved in 2015.
Local, state, and federal officials have embraced naloxone as a lifesaving measure. Cities and states have standing orders that allow pharmacies to give it out without a doctor’s prescription, and officials have tried to put it into the hands of virtually anyone who might encounter a person overdosing, including drug users, police, and even librarians.
CDC researchers noted there were fewer than 1,300 naloxone prescriptions dispensed in 2012, meaning the number grew more than 430-fold in six years.
Health officials said pharmacies should be giving out even more.
“We don’t think anybody is at the level we’d like to see them,” said Dr. Anne Schuchat of the Centers for Disease Control and Prevention.
The CDC report is based on data from IQVIA, a company that tracks health care information, and looked at prescriptions from more than 50,000 retail pharmacies across the country. It included both prescriptions written by doctors for specific patients and those filled under the broader standing orders.
The report offers only a partial picture, however, since only about 20% of naloxone was sold to retail pharmacies in 2017, according to an earlier government report.
Still, it’s the CDC’s first close look at where most retail dispensing is happening. The agency provided data for about 2,900 of the nation’s 3,100 counties and parishes.
The researchers found it was most common in cities, and in the South.
Experts said the findings likely reflect a number of factors. More naloxone is likely prescribed in places where more people are using opioids and where policies increase access.
Of the 30 counties with the highest rate of naloxone dispensing in 2018, 13 were in Virginia and five were in Kentucky. But the highest naloxone dispensing rate was in Marshall County, Ind., according to the CDC data.
The CDC recommends that naloxone be prescribed to patients who are getting high-dose opioids and are at risk for an overdose. It noted that only one naloxone prescription is written for every 69 high-dose opioid prescriptions.
Another finding: The number of high-dose opioid prescription painkillers dispensed fell to about 38 million last year, from nearly 49 million the year before.
That likely also contributed to the decline in overdose deaths last year, Schuchat said.
—How the maker of the world’s bestselling drug keep prices sky-high
—As the opioid crisis grew, manufacturers supplied and doctors prescribed stronger pills
—Trump administration to allow Americans to get cheaper drugs from Canada
—Why Heineken and Budweiser are killing it with zero-alcohol beer
—Listen to our audio briefing, Fortune 500 Daily
Follow Fortune on Flipboard to stay up-to-date on the latest news and analysis.
